Cited 7 times in
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민유홍 | - |
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2016-02-04T11:48:54Z | - |
dc.date.available | 2016-02-04T11:48:54Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0001-5792 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141264 | - |
dc.description.abstract | Azacitidine (AZA) is commonly used in patients with myelodysplastic syndrome (MDS). To determine the role of AZA before allogeneic stem cell transplantation (allo-SCT), we conducted a prospective study of AZA pre-treatment followed by allo-SCT in patients with higher-risk MDS. Twenty-one patients who were scheduled for their third to sixth cycle of AZA pre-treatment followed by allo-SCT were enrolled. AZA pre-treatment was interrupted early in 3 patients (14.3%) because of leukaemic transformation or death. The overall response rate to AZA pre-treatment was 57.1%. There were 2 cases of complete remission, 1 case of partial remission, and 9 cases of haematologic improvement. Fourteen patients (66.7%) received the planned allo-SCT and 5 patients were alive at the last follow-up. Three-year progression-free survival (PFS) and 3-year overall survival (OS) in the 14 patients who received allo-SCT were 30.0% (95% CI 3.3-56.7) and 42.9% (95% CI 17.1-68.7), respectively. PFS and OS were not influenced by response to AZA pre-treatment (p > 0.05). In this study, AZA had a role as a bridge therapy to prevent leukaemic transformation prior to selection of a donor for allo-SCT and showed low toxicity. It may be considered in patients with higher-risk MDS. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 40~48 | - |
dc.relation.isPartOf | ACTA HAEMATOLOGICA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Allografts | - |
dc.subject.MESH | Antimetabolites, Antineoplastic* | - |
dc.subject.MESH | Azacitidine*/administration & dosage | - |
dc.subject.MESH | Azacitidine*/adverse effects | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myelodysplastic Syndromes*/mortality | - |
dc.subject.MESH | Myelodysplastic Syndromes*/pathology | - |
dc.subject.MESH | Myelodysplastic Syndromes*/therapy | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Stem Cell Transplantation* | - |
dc.subject.MESH | Survival Rate | - |
dc.title | Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Ahn J.-S. | - |
dc.contributor.googleauthor | Kim Y.-K. | - |
dc.contributor.googleauthor | Min Y.H. | - |
dc.contributor.googleauthor | Cheong J.-W. | - |
dc.contributor.googleauthor | Jang J.H. | - |
dc.contributor.googleauthor | Jung C.W. | - |
dc.contributor.googleauthor | Kim I.H. | - |
dc.contributor.googleauthor | Yoon H.-J. | - |
dc.contributor.googleauthor | Lee H.G. | - |
dc.contributor.googleauthor | Sohn S.K. | - |
dc.contributor.googleauthor | Moon J.H. | - |
dc.contributor.googleauthor | Kim H.h | - |
dc.contributor.googleauthor | Kim Y.-J. | - |
dc.contributor.googleauthor | Won J.-H. | - |
dc.contributor.googleauthor | Chung J.-S. | - |
dc.contributor.googleauthor | Mun Y.C. | - |
dc.contributor.googleauthor | Lee J.-H. | - |
dc.contributor.googleauthor | Kim H.-J. | - |
dc.identifier.doi | 10.1159/000368711 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01407 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J00014 | - |
dc.identifier.eissn | 1421-9662 | - |
dc.identifier.pmid | 26066466 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/368711 | - |
dc.subject.keyword | Myelodysplastic syndrome | - |
dc.subject.keyword | Azacitidine | - |
dc.subject.keyword | Allogeneic stem cell transplantation | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 134 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 40 | - |
dc.citation.endPage | 48 | - |
dc.identifier.bibliographicCitation | ACTA HAEMATOLOGICA, Vol.134(1) : 40-48, 2015 | - |
dc.identifier.rimsid | 31446 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.